Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response

Li, Li; Ma, Li; Shang, Dan; Liu, Zhiguo; Yu, Qingxi; Wang, Shuzhen; Teng, Xuepeng; Zhang, Qiang; Hu, Xudong; Zhao, Wei; Hou, Wei; Jin, Jian-Yue; Kong, Feng-Ming; Yu, Jinming; Yuan, Shuanghu

doi:10.1007/s00259-018-4143-8

Cited by 29 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our quanti cation of immunohistochemical staining in primary tumor showed that the expression of VEGF and Ki67 in LoVo tissues were stronger than LS174T ones, combined with the results of correlation analysis, a weak correlation between 18 F-RGD SUVmean ratio and Ki67 expression (P = 0.0438) and a strongly signi cant correlation between RGD SUVmax ratio/SUVmean ratio and VEGF expression in primary tumor (P = 0.001 and P 0.0001, respectively), indicating that the SUVmax ratio/SUVmean ratio of 18 F-RGD may be recognized as an ideal radiation maker to re ect tumor angiogenesis in CLM mice model. Our viewpoint was consistent with previous reviews, that 18 F-RGD is a promising tracer for tumor angiogenesis imaging and monitoring anti-angiogenesis therapy in solid tumor [25,26]. In Sibel lsal's study, they also veri ed that the expression of integrin αvβ3, which are targeted by RGD-based peptides tracer, was associated with cell proliferation in glioblastoma [27].…”

Section: Discussionsupporting

confidence: 91%

Micro-PET imaging of angiogenesis based on 18F-RGD for assessment liver metastasis in colorectal cancer

Zhang¹,

Jiang²,

Jiang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: This study aimed to explore the feasibility of 18 F-AIF-NOTA-E[PEG4-c(RGDfk)]2 (denoted as 18 F-RGD) PET quantitative parameters to distinguish the angiogenesis in colorectal cancer (CRC) mice which has different metastatic potential. Methods: Animal models of CRC liver metastases were established by implanttation of human CRC cell lines LoVo and LS174T via intrasplenic injection. Radiotracer-based micro-positron emission tomography imaging of animal model was performed and the uptake of 18 F-RGD tracer in the tumor tissues were quantified as tumor-to-liver maximum or mean standardized uptake values ratio. Pearson correlation was used to analyze the relationship between radioactive parameters and tumor markers. Results: The SUVmax ratio and SUVmean ratio of LoVo model was significantly higher than LS174T ones in both liver metastasis and primary tumor lesions (P ＜ 0.05 ). A significantly difference was observed in both VEGF and Ki67 expression between LoVo and LS174T primary tumors (P ＜ 0.05 ). The T/L SUVmean or SUVmax ratio of 18 F-RGD showed a significantly correlation with VEGF expression, but weakly correlated with Ki67 expression. The areas under the ROC curves of 18 F-RGD SUVmean ratio for differentiate LoVo from LS174T tumor was 0.801. Conclusions: The T/L SUVmean ratio of 18 F-RGD is a promising parameters for tumor imaging and monitoring angiogenesis process in CRC xenograft mice model.

show abstract

Section: Discussionsupporting

confidence: 91%

Micro-PET imaging of angiogenesis based on 18F-RGD for assessment liver metastasis in colorectal cancer

Zhang¹,

Jiang²,

Jiang³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Another study in 61 patients with esophageal squamous cell carcinoma found quite similar results but stated that alfatide I could still provide complementary molecular information about the metastasis of this cancer [198]. Recently, alfatide I PET imaging was shown to possibly be predictable of the response to antiangiogenic agent apatinib [199].…”

Section: Current Clinical Use Of [18f]alf-labeled Biomoleculesmentioning

confidence: 89%

A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [18F]fluoride: Will [18F]AlF Replace 68Ga for Metal Chelate Labeling?

et al. 2019

View full text Add to dashboard Cite

Due to its ideal physical properties, fluorine-18 turns out to be a key radionuclide for positron emission tomography (PET) imaging, for both preclinical and clinical applications. However, usual biomolecules radiofluorination procedures require the formation of covalent bonds with fluorinated prosthetic groups. This drawback makes radiofluorination impractical for routine radiolabeling, gallium-68 appearing to be much more convenient for the labeling of chelator-bearing PET probes. In response to this limitation, a recent expansion of the 18F chemical toolbox gave aluminum [18F]fluoride chemistry a real prominence since the late 2000s. This approach is based on the formation of an [18F][AlF]2+ cation, complexed with a 9-membered cyclic chelator such as NOTA, NODA or their analogs. Allowing a one-step radiofluorination in an aqueous medium, this technique combines fluorine-18 and non-covalent radiolabeling with the advantage of being very easy to implement. Since its first reports, [18F]AlF radiolabeling approach has been applied to a wide variety of potential PET imaging vectors, whether of peptidic, proteic, or small molecule structure. Most of these [18F]AlF-labeled tracers showed promising preclinical results and have reached the clinical evaluation stage for some of them. The aim of this report is to provide a comprehensive overview of [18F]AlF labeling applications through a description of the various [18F]AlF-labeled conjugates, from their radiosynthesis to their evaluation as PET imaging agents.

show abstract

“…At present, the targeted drugs for anti-angiogenesis therapy in breast cancer have been used in clinical research [19]. Imaging based on integrin α v β 3 found that 18 F-ALT-NOTA-PRGD 2 may predict a better response to apatinib anti-angiogenesis therapy in breast cancer [34]. A receptor imaging by combing diagnosis and monitoring drug response may be a valid instrument to select breast cancer patients who could bene t from targeted therapies [35].…”

Section: Discussionmentioning

confidence: 99%

Application of 99mTc-3PRGD2 Imaging for Early Prediction of Pathological Response to Neoadjuvant Chemotherapy in Breast Tumors and Axillary Lymph Nodes

Chen

Lin

et al. 2020

Preprint

View full text Add to dashboard Cite

Background and PurposeTechnetium 99m-dimeric cyclic RGD peptides with three polyethylene glycol spacers (99mTc-3PRGD2) had a good performance for diagnosing breast cancer. The prospective study was to assess the performance of 99mTc-3PRGD2 tumor imaging for predicting pathological complete response (pCR) outcomes to neoadjuvant chemotherapy (NAC) in breast cancer patients.Materials and MethodsForty-one patients were examined using both 99mTc-3PRGD2 and 18F-fluoro-deoxy-glucose (18F-FDG) imaging before NAC (baseline), and after the first and fifth NAC cycle. The tumor-to-background (T/B) ratios for 99mTc-3PRGD2 imaging and the maximum standardized uptake values (SUVmax) from the 18F-FDG imaging in breast tumors and axillary lymph node (ALN) metastases were separately calculated and analyzed—based on receiver operating characteristic (ROC) analysis. ResultsFinally, pCR was achieved in 13 of 41 patients after NAC. The area under curve (AUC) of T/B changes (ΔT/B) in breast tumors for predicting pCR after first and fifth cycle were 0.827 and 0.687, and 0.859 and 0.778 in ALN metastases, respectively. For SUVmax changes (ΔSUVmax), the ROC-AUC were 0.859 and 0.713, as well as 0.572 and 0.802, respectively. In breast tumors, the AUCs of ΔT/B1 and ΔSUVmax1 had no significant difference (P > 0.05). However, the AUC of ΔT/B1 was significantly higher than for ΔSUVmax1 in ALN metastases (Z = 2.10, P = 0.035). Additionally, the T/B1 trends for breast tumor and ALN in pCR group were higher than for non-pCR group in HER2-positive patients (P﹤0.05). ConclusionsCompared with 18F-FDG imaging, our study shows that use of 99mTc-3PRGD2 imaging offered a similar level of predictive performance for breast cancer pCR to NAC, and early T/B1 trends of ALN showed an higher performance for predicting pCR.Trial RegistrationClinicalTrials.gov ID: NCT02742168.

show abstract

Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response

Abstract: F-RGD uptake on PET/CT imaging pretreatment may predict the response to antiangiogenic therapy, with higher F-RGD uptake in tumors predicting a better response to apatinib therapy.

Cited by 29 publications

References 25 publications

Micro-PET imaging of angiogenesis based on 18F-RGD for assessment liver metastasis in colorectal cancer

Micro-PET imaging of angiogenesis based on 18F-RGD for assessment liver metastasis in colorectal cancer

A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [18F]fluoride: Will [18F]AlF Replace 68Ga for Metal Chelate Labeling?

Application of 99mTc-3PRGD2 Imaging for Early Prediction of Pathological Response to Neoadjuvant Chemotherapy in Breast Tumors and Axillary Lymph Nodes

Contact Info

Product

Resources

About